Presentation is loading. Please wait.

Presentation is loading. Please wait.

Management of Neuromuscular Disorders February 2007.

Similar presentations


Presentation on theme: "Management of Neuromuscular Disorders February 2007."— Presentation transcript:

1 Management of Neuromuscular Disorders February 2007

2 Neuromuscular Disorders Myasthenia gravis (14/100,000) Myasthenia gravis (14/100,000) Multiple sclerosis ( Multiple sclerosis (1/1000) Motor neurone disease ( Motor neurone disease (4.0 per 100,000) Others: spasticity; restless legs

3 Myasthenia Gravis women in their 20s and 30s and men over the age of 60 women in their 20s and 30s and men over the age of 60 muscle weakness increases with exercise and improves with rest muscle weakness increases with exercise and improves with rest often begins in the eyes, but may begin in the bulbar muscles or the muscles of the limbs and trunk often begins in the eyes, but may begin in the bulbar muscles or the muscles of the limbs and trunk acetylcholine receptor antibodies 80-90% acetylcholine receptor antibodies 80-90% Repetitive nerve stimulation produces decremental response Repetitive nerve stimulation produces decremental response Penicillamine induces a myasthenic syndrome in approximately 1 percent of cases Penicillamine induces a myasthenic syndrome in approximately 1 percent of cases Penicillamine

4 A patient with myasthenia gravis produces autoantibodies to the acetylcholine receptors on the motor end-plates of muscles. Binding of acetylcholine is blocked and muscle activation is inhibited. The autoantibodies also induce complement-mediated degradation of the acetylcholine receptors, resulting in progressive weakening of the skeletal muscles.

5 Acetylcholinesterase inhibitors Walker MB Lancet 1934 1:1200-1201

6 Diagnosis- Edrophonium test Acetylcholinesterase inhibitor Tensilon (edrophonium chloride) Acetylcholinesterase inhibitor Tensilon (edrophonium chloride)edrophonium Onset of action 30 to 60 seconds ; duration five to 10 minutes Onset of action 30 to 60 seconds ; duration five to 10 minutes s/e bradycardia, asystole and bronchoconstriction s/e bradycardia, asystole and bronchoconstriction Require cardiac monitoring and resuscitation facilities during the test Require cardiac monitoring and resuscitation facilities during the test Atropine (0.5 to 2.0 mg) should be available if a severe cholinergic reaction occurs (sweating, increased weakness and respiratory secretions, laryngospasm, bradycardia, hypotension, nausea, and vomiting) Atropine (0.5 to 2.0 mg) should be available if a severe cholinergic reaction occurs (sweating, increased weakness and respiratory secretions, laryngospasm, bradycardia, hypotension, nausea, and vomiting) Atropine Test dose of 1 mg (0.1 mL) of Tensilon should be given. After one minute, a further 4 mg (0.4 mL) is given and, if no change in the examination is noted in one minute, the remainder of the vial (5 mg, 0.5 mL) Test dose of 1 mg (0.1 mL) of Tensilon should be given. After one minute, a further 4 mg (0.4 mL) is given and, if no change in the examination is noted in one minute, the remainder of the vial (5 mg, 0.5 mL)

7 Treatment modalities anticholinesterase medications (cholinesterase inhibitors) – symptomatic treatment anticholinesterase medications (cholinesterase inhibitors) – symptomatic treatment immunosuppression and/or thymectomy – induce remission immunosuppression and/or thymectomy – induce remission

8 Cholinesterase inhibitors increase the availability of acetylcholine, partially overcome the decreased receptor availability increase the availability of acetylcholine, partially overcome the decreased receptor availability Eg Edrophonium, Neostigmine, Pyridostigmine, Distigmine Eg Edrophonium, Neostigmine, Pyridostigmine, Distigmine (in order of increasing duration of action) (in order of increasing duration of action) Onset of action is usually within 30 minutes and peak action occurs at about two hours (pyridostigmine) Onset of action is usually within 30 minutes and peak action occurs at about two hours (pyridostigmine) s/e dose-related muscarinic; colic; diarrhoea; sialorrhoea; miosis; sweating; cholinergic crisis s/e dose-related muscarinic; colic; diarrhoea; sialorrhoea; miosis; sweating; cholinergic crisis Greater risk with longer acting agents Greater risk with longer acting agents

9 Cholinesterase inhibitors First line for ocular myasthenia First line for ocular myasthenia Adjunct to immunosuppression for generalised myasthenia Adjunct to immunosuppression for generalised myasthenia

10 Thymectomy Hyperplasia in 60 to 70 percent Hyperplasia in 60 to 70 percent Thymoma in 10 to 12 percent Thymoma in 10 to 12 percent Thymoma excision/ radiotherapy Thymoma excision/ radiotherapy Must ensure complete removal of the thymus Must ensure complete removal of the thymus Transient postoperative worsening of myasthenic symptoms is well recognized Transient postoperative worsening of myasthenic symptoms is well recognized

11 Immunosuppressive Agents Corticosteroids produces remission in about 30% & improvement in another 45% Corticosteroids produces remission in about 30% & improvement in another 45% Transient worsening of symptoms can occur any time in the first three weeks Transient worsening of symptoms can occur any time in the first three weeks Azathioprine/cyclosporine/mycophenolate/ tacrolimus Azathioprine/cyclosporine/mycophenolate/ tacrolimus Suppress T-cell activity and are effective in myasthenia because AChR-Ab production is T-cell dependent Suppress T-cell activity and are effective in myasthenia because AChR-Ab production is T-cell dependent

12 Plasmapheresis Directly removes AChR-Ab from the circulation and its clinical efficacy roughly correlates with the reduction in AChR-Ab levels Directly removes AChR-Ab from the circulation and its clinical efficacy roughly correlates with the reduction in AChR-Ab levels A typical course of treatment consists of a two to four liter exchanges two to three times per week for two weeks A typical course of treatment consists of a two to four liter exchanges two to three times per week for two weeks Transient, usually lasting only one to two months Transient, usually lasting only one to two months

13 Intravenous immune globulin pooled human plasma from screened donors (theoretical x- infection) pooled human plasma from screened donors (theoretical x- infection) same setting as plasmapheresis to quickly reverse an exacerbation of myasthenia same setting as plasmapheresis to quickly reverse an exacerbation of myasthenia s/e headache or fluid retention aseptic meningitis, renal failure, haemolysis, anaphylaxis s/e headache or fluid retention aseptic meningitis, renal failure, haemolysis, anaphylaxis

14 Myasthenic crisis life-threatening condition characterized by respiratory and pharyngeal muscle paresis life-threatening condition characterized by respiratory and pharyngeal muscle paresis Spontaneous; intercurrent illness; after initiation of therapy Spontaneous; intercurrent illness; after initiation of therapy Elective intubation to treat respiratory depression Elective intubation to treat respiratory depression Withdrawal of all anticholinesterase medication for several days Withdrawal of all anticholinesterase medication for several days Plasmapheresis or IVIG Plasmapheresis or IVIG

15 Lambert-Eaton myasthenic syndrome Paraneoplastic (esp small cell lung CA) Paraneoplastic (esp small cell lung CA) Gradual onset of hip girdle weakness /Oculobulbar involvement is rare Gradual onset of hip girdle weakness /Oculobulbar involvement is rare Improves during the day and with exercise Improves during the day and with exercise Repetitive nerve stimulation produces an incremental response Repetitive nerve stimulation produces an incremental response Antibodies directed against P/Q-type presynaptic voltage-gated calcium channels Antibodies directed against P/Q-type presynaptic voltage-gated calcium channels Treatment: remove or treat the cancer Treatment: remove or treat the cancer Plasma exchange and IV immune globulin Plasma exchange and IV immune globulin 3,4-diaminopyridine (DAP), which promotes the release of acetylcholine from presynaptic terminals 3,4-diaminopyridine (DAP), which promotes the release of acetylcholine from presynaptic terminals Long-term immunotherapy Long-term immunotherapy

16 Multiple Sclerosis relapsing remitting autoimmune inflammatory demyelinating disease of the central nervous system relapsing remitting autoimmune inflammatory demyelinating disease of the central nervous system

17

18 Acute attacks mild sensory attacks are usually not treated mild sensory attacks are usually not treated Treatment with short courses of intravenous methylprednisolone, 500 to 1000 mg daily for three to seven days, with or without a short prednisolone taper Treatment with short courses of intravenous methylprednisolone, 500 to 1000 mg daily for three to seven days, with or without a short prednisolone taper methylprednisoloneprednisolone methylprednisoloneprednisolone mental changes, unmasking of infections, and gastric disturbances; anaphylactoid reactions and arrhythmias; osteoporosis with repeated therapy mental changes, unmasking of infections, and gastric disturbances; anaphylactoid reactions and arrhythmias; osteoporosis with repeated therapy Plasma exchange Plasma exchange

19 Disease Modifying therapy decreased relapse rate decreased relapse rate reduced progression of disability reduced progression of disability slower accumulation of lesions on MRI slower accumulation of lesions on MRI reduced relapse by 28% to 66% reduced relapse by 28% to 66% £7000- £10000 per annum £7000- £10000 per annum Interferons, glatiramer, mitoxantrone (USA), natalizumab Interferons, glatiramer, mitoxantrone (USA), natalizumab

20 Beta interferon recombinant IFNB-1b (Betaferon) IFNB-1a (Avonex, Rebif) recombinant IFNB-1b (Betaferon) IFNB-1a (Avonex, Rebif) s/c or im self injection s/c or im self injection cytokine that modulates immune responsiveness, although its precise mechanism of action in MS is unknown cytokine that modulates immune responsiveness, although its precise mechanism of action in MS is unknown annual exacerbation rate significantly lower (30%) annual exacerbation rate significantly lower (30%) administered every other day subcutaneously by self injection administered every other day subcutaneously by self injection 34 percent of patients develop neutralizing antibodies 34 percent of patients develop neutralizing antibodies s/e local reactions; flu-like symptoms; abnormal LFTS s/e local reactions; flu-like symptoms; abnormal LFTS

21 Beta interferon - indications single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis relapsing remitting multiple sclerosis and two or more relapses within the last two years. relapsing remitting multiple sclerosis and two or more relapses within the last two years. secondary progressive multiple sclerosis with active disease, evidenced by relapses secondary progressive multiple sclerosis with active disease, evidenced by relapses

22 Glatiramer (Copaxone) mixture of random polymers of four amino acids mixture of random polymers of four amino acids antigenically similar to myelin basic protein antigenically similar to myelin basic protein binding to major histocompatibility complex (MHC) molecules and consequent competition with various myelin antigens for their presentation to T cells binding to major histocompatibility complex (MHC) molecules and consequent competition with various myelin antigens for their presentation to T cells potent inducer of specific T helper 2 type suppressor cells potent inducer of specific T helper 2 type suppressor cells 32% reduction in relapse rate 32% reduction in relapse rate

23 Glatiramer (Copaxone) Indications: Indications: relapsing, remitting multiple sclerosis (MS) characterised by at least two attacks of neurological dysfunction over the preceding two-years relapsing, remitting multiple sclerosis (MS) characterised by at least two attacks of neurological dysfunction over the preceding two-years Daily subcutaneous injectable synthetic polymer Daily subcutaneous injectable synthetic polymer Adverse reactions: Adverse reactions: local reactions; chest pain, flushing, dyspnea, palpitations, anxiety local reactions; chest pain, flushing, dyspnea, palpitations, anxiety

24 Natalizumab (Tysabri) alpha-4 integrin antagonist (leucocyte adhesion molecule) alpha-4 integrin antagonist (leucocyte adhesion molecule) expressed on the surface of inflammatory lymphocytes and monocytes expressed on the surface of inflammatory lymphocytes and monocytes 66% relapse reduction 66% relapse reduction voluntarily withdrawn from US market 2005 voluntarily withdrawn from US market 2005 Approved EU 2006 Approved EU 2006 PML (JC virus)

25 Natalizumab (Tysabri) Indications: Indications: High disease activity despite treatment with a beta-interferon High disease activity despite treatment with a beta-interferon Rapidly evolving severe relapsing remitting multiple sclerosis Rapidly evolving severe relapsing remitting multiple sclerosis Monthly IV infusion Monthly IV infusion C/I: C/I: Concomitant beta-interferon or glatiramir Concomitant beta-interferon or glatiramir Adverse reactions: Adverse reactions: progressive multifocal leukoencephalopathy (PML); Opportunistic progressive multifocal leukoencephalopathy (PML); Opportunistic infections; antibodies 10% infections; antibodies 10%

26 Mitoxantrone anthracycline analogue; intercalates DNA; inhibits DNA and RNA synthesis anthracycline analogue; intercalates DNA; inhibits DNA and RNA synthesis Chemotherapeutic agent Chemotherapeutic agent Trial: IV treatment (5 mg/m2 or 12 mg/m2) every three months for two years – progressive MS Trial: IV treatment (5 mg/m2 or 12 mg/m2) every three months for two years – progressive MS reducing progression of disability and clinical exacerbations reducing progression of disability and clinical exacerbations cardiotoxicity and Secondary Leukemia (AML) prevents prolonged usage cardiotoxicity and Secondary Leukemia (AML) prevents prolonged usage s/e blue-green urine s/e blue-green urine

27 “…the luckiest man on the face of the earth”

28 Motor neurone disease

29 MND/ALS progressive degeneration of the motor neurones of the brain, brain stem or spinal cord progressive degeneration of the motor neurones of the brain, brain stem or spinal cord Variants - Variants - amyotrophic lateral sclerosis (ALS) 65-85% amyotrophic lateral sclerosis (ALS) 65-85% progressive bulbar palsy (PBP) progressive bulbar palsy (PBP) progressive muscular atrophy (PMA) progressive muscular atrophy (PMA) Death usually within 3 years from ventilatory failure Death usually within 3 years from ventilatory failure

30 Amyotrophic lateral sclerosis LMN findings of weakness, atrophy, and fasciculations are a direct consequence of muscle denervation LMN findings of weakness, atrophy, and fasciculations are a direct consequence of muscle denervation UMN findings of hyperreflexia and spasticity result from degeneration of the lateral corticospinal tracts in the spinal cord UMN findings of hyperreflexia and spasticity result from degeneration of the lateral corticospinal tracts in the spinal cord

31 Riluzole Mechanism of action is not known Mechanism of action is not known Pharmacologic properties include - Pharmacologic properties include - - inhibitory effect on glutamate release - inhibitory effect on glutamate release (excitatory neurotransmitter) (excitatory neurotransmitter) - inactivation of voltage-dependent sodium channels - inactivation of voltage-dependent sodium channels - ability to interfere with intracellular events that - ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid follow transmitter binding at excitatory amino acid receptors receptors

32 Riluzole Licensed to extend life or the time to mechanical ventilation Licensed to extend life or the time to mechanical ventilation prospective, double-blind, placebo-controlled trial in 155 outpatients with ALS, survival at 12 months was significantly higher for patients receiving riluzole (100 mg/day) compared with controls (74 versus 58 percent, relative risk 0.43, CI 0.24-0.77) prospective, double-blind, placebo-controlled trial in 155 outpatients with ALS, survival at 12 months was significantly higher for patients receiving riluzole (100 mg/day) compared with controls (74 versus 58 percent, relative risk 0.43, CI 0.24-0.77) s/e hepatic impairment; GI; dizziness; somnolence; neutropaenia s/e hepatic impairment; GI; dizziness; somnolence; neutropaenia 50mg bd; Monitor LFTs 3 monthly 50mg bd; Monitor LFTs 3 monthly

33 Spasticity

34 Spasticity Baclofen Baclofen GABA derivative acting at spinal level GABA derivative acting at spinal level Caution with sedative drugs and antihypertensives – sedation & hypotension Caution with sedative drugs and antihypertensives – sedation & hypotension Hyperglycaemia, confusion, hallucinations Hyperglycaemia, confusion, hallucinations Dantrolene Dantrolene Direct acting skeletal muscle relaxant Direct acting skeletal muscle relaxant s/e: Hepatotoxicity, seizures s/e: Hepatotoxicity, seizures Diazepam Diazepam Tizanidine Tizanidine α2 -adrenergic receptor agonist within the central nervous system α2 -adrenergic receptor agonist within the central nervous system at supra-spinal and spinal levels at supra-spinal and spinal levels inhibition of spinal polysynaptic reflex activity inhibition of spinal polysynaptic reflex activity Botox Botox

35 Restless legs syndrome Ropinerole Ropinerole D2/D3 dopamine agonist D2/D3 dopamine agonist Stimulates striatal dopamine receptors Stimulates striatal dopamine receptors Cytochrome P450 isoenzyme CYP1A2 eg ciprofloxacin Cytochrome P450 isoenzyme CYP1A2 eg ciprofloxacin Adverse reactions: paradoxical worsening; CNS Adverse reactions: paradoxical worsening; CNS Quinine sulphate Quinine sulphate nocturnal leg cramps nocturnal leg cramps


Download ppt "Management of Neuromuscular Disorders February 2007."

Similar presentations


Ads by Google